Mai A, Sbardella G, Artico M, Ragno R, Massa S, Novellino E, Greco G, Lavecchia A, Musiu C, La Colla M, Murgioni C, La Colla P, Loddo R
Istituto Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Studi Farmaceutici, Università degli Studi di Roma La Sapienza, P.le A. Moro 5, I-00185 Roma, Italy.
J Med Chem. 2001 Aug 2;44(16):2544-54. doi: 10.1021/jm010853h.
5-Alkyl-2-(alkylthio)-6-(2,6-difluorobenzyl)-3,4-dihydropyrimidin-4(3H)-ones (S-DABOs, 2) have been recently described as a new class of human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs) active at nanomolar concentrations (Mai, A. et al. J. Med. Chem. 1999, 42, 619-627). In pursuing our lead optimization efforts, we designed novel conformationally restricted S-DABOs, 3, featuring a methyl at the benzylic carbon (Y = Me) and at the pyrimidine 5-position (R = Me). Conformational analyses and docking simulations suggested that the presence of both methyls would significantly reduce conformational flexibility without compromising, in the R enantiomers, the capability of fitting into the RT non-nucleoside binding pocket. To develop structure-activity relationships, we prepared several congeners of type 3 belonging to the thymine (R = Me) and uracil (R = H) series, featuring various 2-alkylthio side chains (X = Me, i-Pr, n-Bu, i-Bu, s-Bu, c-pentyl, and c-hexyl) and aryl moieties different from the 2,6-difluorophenyl (Ar = phenyl, 2,6-dichlorophenyl, 1-naphthyl). Moreover, alpha-ethyl derivatives (Y = Et) were included in the synthetic project in addition to alpha-methyl derivatives (Y = Me). All of the new compounds were evaluated for their cytotoxicity and anti-HIV-1 activity in MT-4 cells, and some of them were assayed against highly purified recombinant wild-type HIV-1 RT using homopolymeric template primers. The results were expressed as CC(50) (cytotoxicity), EC(50) (anti-HIV-1 activity), SI (selectivity, given by the CC(50)/EC(50) ratio), and IC(50) (RT inhibitory activity) values. In the 2,6-difluorobenzylthymine (R = Me) series, methylation of the benzylic carbon improved anti-HIV-1 and RT inhibitory activities together with selectivity. Compound 3w (Ar = 2,6-F(2)-Ph, R = Y = Me, X = c-pentyl) turned out the most potent and selective among the S-DABOs reported to date (CC(50) > 200 microM, EC(50) = 6 nM, IC(50) = 5 nM, and SI > 33 333). Assays performed on the pure enantiomer (+)-3w, much more active than (-)-3w, yielded the following results: CC(50) > 200 microM, EC(50) = 2 nM, IC(50) = 8 nM, and SI > 100 000, under conditions wherein MKC-442 was less active and selective (CC(50) > 200 microM, EC(50) = 30 nM, IC(50) = 40 nM, SI > 6666). The 2,6-difluorophenylethylthymines (R = Me) were generally endowed with higher potency compared with the uracil counterparts (R = H). In the 2,6-difluorophenyl series the best and the least performant 2-alkylthio side chains were the 2-c-pentylthio and the 2-methylthio, respectively. When the methyl at the benzylic carbon was replaced by an ethyl, activity was retained or decreased slightly, thus suggesting that the dimensions of the cavity within the RT hosting this substituent would not be compatible with groups larger than ethyl. Aryl moieties different from the 2,6-difluorophenyl (phenyl, 1-naphthyl, 2,6-dichlorophenyl) were generally detrimental to activity, consistent with a favorable electronic effect exerted by the 2,6-fluorines on a putative charge-transfer interaction between the aromatic moieties of the inhibitor and Tyr188.
5-烷基-2-(烷硫基)-6-(2,6-二氟苄基)-3,4-二氢嘧啶-4(3H)-酮(S-DABOs, 2)最近被描述为一类新型的人类免疫缺陷病毒1型(HIV-1)非核苷逆转录酶(RT)抑制剂(NNRTIs),在纳摩尔浓度下具有活性(Mai, A.等人,《药物化学杂志》,1999年,42卷,619 - 627页)。在进行先导化合物优化工作时,我们设计了新型的构象受限S-DABOs,即3,其苄基碳(Y = Me)和嘧啶5位(R = Me)上均有一个甲基。构象分析和对接模拟表明,两个甲基的存在将显著降低构象灵活性,而在R对映体中,这并不影响其与RT非核苷结合口袋的契合能力。为了建立构效关系,我们制备了几种3型同系物,它们属于胸腺嘧啶(R = Me)和尿嘧啶(R = H)系列,具有各种2-烷硫基侧链(X = Me、i-Pr、n-Bu、i-Bu、s-Bu、环戊基和环己基)以及不同于2,6-二氟苯基的芳基部分(Ar = 苯基、2,6-二氯苯基、1-萘基)。此外,除了α-甲基衍生物(Y = Me)外,α-乙基衍生物(Y = Et)也被纳入合成方案中。所有新化合物均在MT-4细胞中评估了其细胞毒性和抗HIV-1活性,其中一些化合物使用同聚模板引物针对高度纯化的重组野生型HIV-1 RT进行了测定。结果以CC(50)(细胞毒性)、EC(50)(抗HIV-1活性)、SI(选择性,由CC(50)/EC(50)比值给出)和IC(50)(RT抑制活性)值表示。在2,6-二氟苄基胸腺嘧啶(R = Me)系列中,苄基碳的甲基化提高了抗HIV-1和RT抑制活性以及选择性。化合物3w(Ar = 2,6-F(2)-Ph, R = Y = Me, X = 环戊基)是迄今为止报道的S-DABOs中最有效和最具选择性的(CC(50)>200 μM, EC(50)=6 nM, IC(50)=5 nM, SI>33 333)。对纯对映体(+)-3w进行的测定比(-)-3w活性高得多,结果如下:在MKC-442活性和选择性较低(CC(50)>200 μM, EC(50)=30 nM, IC(50)=40 nM, SI>6666)的条件下,CC(50)>200 μM, EC(50)=2 nM, IC(50)=8 nM, SI>100 000。与尿嘧啶类似物(R = H)相比,2,6-二氟苯乙基胸腺嘧啶(R = Me)通常具有更高的活性。在2,6-二氟苯基系列中,最好和表现最差的2-烷硫基侧链分别是2-环戊硫基和2-甲硫基。当苄基碳上的甲基被乙基取代时,活性得以保留或略有下降,这表明RT中容纳该取代基的腔内尺寸与大于乙基的基团不相容。不同于2,6-二氟苯基的芳基部分(苯基、1-萘基、2,6-二氯苯基)通常对活性不利,这与2,6-氟原子对抑制剂芳基部分与Tyr188之间假定的电荷转移相互作用产生的有利电子效应一致。